

**COMMONWEALTH OF KENTUCKY STATE FISCAL NOTE STATEMENT
LEGISLATIVE RESEARCH COMMISSION
2018 REGULAR SESSION**

MEASURE

2018 BR NUMBER **0268**

HOUSE BILL NUMBER **246/HCS1**

RESOLUTION NUMBER _____

AMENDMENT NUMBER _____

SUBJECT/TITLE **An ACT relating to medication-assisted therapy in community pharmacies.**

SPONSOR **Representative Bentley**

NOTE SUMMARY

FISCAL ANALYSIS: IMPACT NO IMPACT INDETERMINABLE IMPACT

LEVEL(S) OF IMPACT: STATE LOCAL FEDERAL

BUDGET UNIT(S) IMPACT: _____

FUND(S) IMPACT: GENERAL ROAD FEDERAL RESTRICTED AGENCY _____ OTHER

FISCAL SUMMARY

FISCAL ESTIMATES	2017-2018	2018-2019	2019-2020	ANNUAL IMPACT AT FULL IMPLEMENTATION
REVENUES				
EXPENDITURES				
NET EFFECT				

() indicates a decrease/negative

MEASURE'S PURPOSE: The purpose of this bill is to establish a pilot program to analyze the outcomes and effectiveness of a community pharmacy care delivery model for medication-assisted therapy for the treatment of substance abuse.

PROVISIONS/MECHANICS: Section 1 creates a new section of KRS 194A to explain the purpose and provide the parameters for establishing the pilot program. Section 1, Subsections (1) and (2) define "pilot program" and indicate the purpose of establishing the pilot program. Subsection (3) specifies that the Department for Medicaid Services (DMS) and the Medicaid managed care organizations will provide claims data for analysis to determine the outcomes and effectiveness of the program. Subsection (4) requires the Cabinet for Health and Family Services to initiate the pilot program, but specifies the implementation of this program is based on whether funds are available. This section continues by outlining program components. These components include a wraparound services model that engages psychological and social support and the establishment of collaborative relationships with detention facilities, drug courts,

community pharmacists, and practitioners. Subsection (5) requires the Cabinet for Health and Family Services to provide a joint report to the Legislative Research Commission and the Office of the Governor by December 31, 2019.

Section 2, Subsection (1) creates a new section of KRS 205 preventing the requirement of prior authorization for non-controlled medication-assisted therapies for community pharmacies in regards to the pilot program. Subsection (2) prevents exclusions, mandates or restrictions from being placed upon pharmacies or pharmacists participating in this program by Medicaid managed care organizations or its contracted pharmacy benefit manager.

FISCAL EXPLANATION: HB 246/HCS1 will not have a fiscal impact on the Cabinet for Health and Family Services, as it codifies the requirement for an existing grant-funded project. The bill does not pose a fiscal impact to DMS, as only medications that are already covered by DMS will be available through the pilot program.

DATA SOURCE(S): Cabinet for Health and Family Services

PREPARER: Jake Fouts **NOTE NUMBER:** 128 **REVIEW:** JAB **DATE:** 3/5/2018

LRC 2018-BR0268-HB246HCS1